Diamondback Drugs
Independently owned retail pharmacy.
Based in AZ
AI Overview
With $45K in lobbying spend across 5 quarterly filings, Diamondback Drugs is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2018 to 2019.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $45K |
| 2019 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Diamondback Drugs disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues, Budget/Appropriations
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.
Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.